Literature DB >> 17502231

Approach to the treatment-experienced patient.

Joel E Gallant1.   

Abstract

The management of treatment-experienced patients is complex and challenging. Fortunately, new agents continue to be developed that offer hope to those who have developed resistance to currently available agents. Knowing when, how, and in whom to use new agents is never easy and highlights the importance of expert care for HIV-infected patients. The management of treatment-experienced patients requires considerable expertise, especially now that patients with highly resistant virus can hope to achieve full virologic suppression.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17502231     DOI： 10.1016/j.idc.2007.01.003

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  4 in total

1.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.

Authors:  Xavier Colin; Antoine Lafuma; Dominique Costagliola; Erik Smets; Josephine Mauskopf; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.

Authors:  José Ernesto Vidal; Alice Tung Wan Song; Maria Laura Matos; Daniel Bartmann; Guilherme Dos Anjos; Érique José Peixoto de Miranda; Ângela Carvalho Freitas; Mirian de Freitas Dalben; Claudinei Santana; Aluísio Cotrim Segurado; Cláudia Cortese Barreto; Adrián Vladimir Hernández
Journal:  Braz J Infect Dis       Date:  2013-01-05       Impact factor: 3.257
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.